Biomarkers for anti‑vascular endothelial growth factor drugs-Reference-Cited by-同舟云学术

Biomarkers for anti‑vascular endothelial growth factor drugs

Published:2022-11-07 Issue:6 Volume:24 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Kuriyama Sho¹,Yamada Takeshi¹,Matsuda Akihisa¹,Takahashi Goro¹,Iwai Takuma¹,Takeda Kohki¹,Ueda Koji¹,Miyasaka Toshimitsu¹,Yokoyama Yasuyuki²,Shinji Seiichi¹,Sonoda Hiromichi¹,Ohta Ryo²,Yonaga Kazuhide¹,Kanaka Shintaro¹,Yoshida Hiroshi¹

Affiliation:

1. Department of Gastrointestinal and Hepato‑Biliary‑Pancreatic Surgery, Nippon Medical School, Tokyo 113‑8603, Japan

2. Department of Digestive Surgery, Nippon Medical School Musashikosugi Hospital, Kawasaki, Kanagawa 211‑8533, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference28 articles.

1. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

2. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: Results From CALGB/SWOG 80405 (Alliance);Lenz;J Clin Oncol,2019

3. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer;Schwartzberg;J Clin Oncol,2014

4. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study;Saltz;J Clin Oncol,2008

5. Extended RAS analysis of the phase III EPIC trial: Irinotecan + Cetuximab versus irinotecan as second-line treatment for patients with metastatic colorectal cancer;Sobrero;Oncologist,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The tumor microenvironment: shaping cancer progression and treatment response;Journal of Chemotherapy;2024-01-05